Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

Neurology. 2012 Sep 4;79(10):1071-2. doi: 10.1212/01.wnl.0000419501.12719.38.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Female
  • Humans
  • Interferon-beta / therapeutic use*
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / physiopathology*

Substances

  • Antibodies, Monoclonal, Humanized
  • Interferon-beta